摘要
背景与目的:舟山眼镜蛇(Najaatra)毒短链神经毒素被用于临床镇痛,我们采用短链神经毒素,研究其高浓度下有无致突变性,为临床应用的安全性提供依据。材料与方法:应用中国仓鼠肺成纤维细胞(CHL)染色体畸变试验和Ames试验检测短链神经毒素潜在的致突变性。结果:短链神经毒素浓度高于0.64μg/ml时,部分菌株的Ames试验结果呈阳性,高于0.32μg/ml时,部分试验组CHL细胞染色体畸变为阳性,但均远低于阳性对照组,而且回复突变和畸变率与神经毒素的浓度不呈线性关系。结论:从致突变角度考虑,短链神经毒素作为药物在临床应用的剂量水平是安全的。
BACKGROUND ＆ AIM： Sort-chain neurotoxin from Naja atra venom is used clinically for analgesia and the drug is a mixture of several kinds of proteins. In this paper, pure short-chain neurotoxin was obtained and its safety and mutagenicity at high concentration was evaluated for clinical application. MATERIALS AND METHODS： The potential mutagenicity of the short-chian neurotoxin was studied by Ames test and CHL chromosome aberration test. RESULTS： Ames test was positive at neurotoxin concentration over 0.64 μg/ml and CHL chromosome aberration test was positive at neurotoxin concentration higher than 0.32 μg/ ml. Back mutation rate and chromosome aberration rate treated with neurotoxin were much lower than the positive control groups and there was no linear relationship between mutation rate, chromosome aberration rate and neurotoxin concentration. CONCLUSION： If mutagenesis was considered as an important factor, then short-chain neurotoxin was safe as a drug.
出处
《癌变·畸变·突变》
CAS
CSCD
2006年第6期472-474,共3页
Carcinogenesis,Teratogenesis & Mutagenesis
基金
安徽省教育厅自然科学研究项目(No.2005KJ204)
